Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
received:
15
02
2024
accepted:
27
03
2024
revised:
19
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy, resulting in significant morbidity and mortality. In an effort to standardize reporting, the European Hematology Association (EHA) and European Society of Blood and Marrow Transplantation (EBMT) devised the immune effector cell-associated hematotoxicity (ICAHT) grading system, distinguishing between early (day 0-30) and late (after day +30) events based on neutropenia depth and duration. However, manual implementation of ICAHT grading criteria is time-consuming and susceptible to subjectivity and error. To address these challenges, we introduce a novel computational approach, utilizing the R programming language, to automate early and late ICAHT grading. Given the complexities of early ICAHT grading, we benchmarked our approach both manually and computationally in two independent cohorts totaling 1251 patients. Our computational approach offers significant implications by streamlining grading processes, reducing manual time and effort, and promoting standardization across varied clinical settings. We provide this tool to the scientific community alongside a comprehensive implementation guide, fostering its widespread adoption and enhancing reporting consistency for ICAHT.
Identifiants
pubmed: 38627450
doi: 10.1038/s41409-024-02278-3
pii: 10.1038/s41409-024-02278-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15. https://ascopubs.org/doi/abs/10.1200/jco.20.01467
doi: 10.1200/JCO.20.01467
pubmed: 33021872
pmcid: 7655016
Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://www.thelancet.com/article/S0140673621009338/fulltext
doi: 10.1016/S0140-6736(21)00933-8
pubmed: 34175021
Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl J Med. 2021;384:705–16.
doi: 10.1056/NEJMoa2024850
pubmed: 33626253
Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022;141:1675–84.
doi: 10.1182/blood.2022018730
pmcid: 10646768
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.
doi: 10.1056/NEJMoa2116133
pubmed: 34891224
Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643–50.
doi: 10.1038/s41409-019-0487-3
pubmed: 30809033
Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87.
doi: 10.1182/bloodadvances.2020002509
pubmed: 32780846
pmcid: 7422135
Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4:3024–33.
doi: 10.1182/bloodadvances.2020001972
pubmed: 32614964
pmcid: 7362382
Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138:2499–513.
doi: 10.1182/blood.2020010543
pubmed: 34166502
pmcid: 8893508
Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6:6109–19.
doi: 10.1182/bloodadvances.2022008320
pubmed: 35939783
pmcid: 9768247
Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460–9.
pubmed: 36800563
pmcid: 10646792
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023;9:eadg3919.
doi: 10.1126/sciadv.adg3919
pubmed: 37738350
pmcid: 10516499
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, et al. Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865–77.
doi: 10.1182/blood.2023020578
pubmed: 37300386
Vic S, Thibert JB, Bachy E, Cartron G, Gastinne T, Morschhauser F, et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study. Blood Adv. 2024;8:1573–85.
doi: 10.1182/bloodadvances.2023011727
pubmed: 38181767
pmcid: 10982963
Rejeski K, Greco R, Onida F, Sánchez-Ortega I, Bonini C, Sureda A, et al. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere. 2023;7:e889.
doi: 10.1097/HS9.0000000000000889
pubmed: 37125259
pmcid: 10145722
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024;
Schlegel RW, Smit AJ. heatwaveR: a central algorithm for the detection of heatwaves and cold-spells. J Open Source Softw. 2018;3:821.
doi: 10.21105/joss.00821
Smit AJ. Detect event streaks based on specified thresholds [Internet]. 2023 [cited 2023 Dec 20]. Available from: https://tangledbank.netlify.app/blog/2023-11-22-run-lengths/
CIBMTR. CIBMTR forms instructions manual: form 2100 revision 3 [Internet]. [cited 2024 Mar 7]. Available from: https://cibmtr.org/Files/Data-Operations/Retired-Forms-Manuals/2100r3-1.2017.pdf